Pharmacoeconomics of liposomal anthracycline therapy

Charles L. Bennett, Elizabeth A. Calhoun

Research output: Contribution to journalArticlepeer-review

11 Scopus citations

Abstract

Pharmacoeconomic analyses are being used with greater frequency in clinical oncology trials. These analyses provide guidelines for prioritizing competing interventions and allocating health care resources, particularly when deciding whether to use a drug with a higher acquisition cost. For liposomal anthracyclines, the competing treatments are other liposomal anthracyclines and nonliposomal chemotherapy agents with similar activity. Pharmacoeconomic analyses of data from clinical trials in patients with Kaposi's sarcoma determined that the overall cost to achieve objective response was substantially lower with pegylated liposomal doxorubicin (Doxil/Caelyx [PLD]) than with liposomal daunorubicin (DaunoXome [DNX]). Additional economic analyses in patients with ovarian cancer showed that PLD has lower overall treatment costs than topotecan because it is administered less frequently and requires fewer interventions for toxicity. The decision to allocate health care resources to liposomal anthracycline treatment must therefore include consideration of cost-effectiveness and potential cost savings owing to improved tolerability.

Original languageEnglish (US)
Pages (from-to)191-195
Number of pages5
JournalSeminars in Oncology
Volume31
Issue numberSUPPL. 13
DOIs
StatePublished - Dec 2004
Externally publishedYes

ASJC Scopus subject areas

  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Pharmacoeconomics of liposomal anthracycline therapy'. Together they form a unique fingerprint.

Cite this